When administered together with antimalarial medication, an experimental malaria vaccine has been found to protect people in the early clinical trial. The study involved 67 healthy adult test persons, none of whom previously had malaria. The best immune response was shown in a group of nine test persons who received the highest dose of the vaccine three times at four-week intervals. At the end of the trial, all nine of these individuals had 100% protection from the disease, according to the study published in the journal Nature.
Study leader from German Centre for Infection Research that by vaccinating with a live, fully active pathogen, it seems clear that we were able to set a very strong immune response. Additionally, all the data we have so far indicate that what we have here is relatively stable, long-lasting protection. In the group of test persons who demonstrated 100% protection…
